Germany· DE-A57-c82377d0e3df71e1
Teglutik
A riluzole product containing riluzole, registered in Germany by Italfarmaco S.A.. The same ATC class is registered in 17 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Riluzole is registered in 17 of 19 countries.
Countries holding a registration under ATC N07XX02 (riluzole), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 10 of them publish a price we can compare per daily dose
Riluzole · ATC N07XX02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of riluzole costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), the median price runs from $5.62 in France to $9.14 in Italy — a ×1.6 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Riluzole · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- IT Italy$9.14
- CH Switzerland$8.63
- FR France$5.62
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Riluzole
- Manufacturer
- Italfarmaco S.A.
- Country
- Germany (DE)
- ATC code
- N07XX02
- ATC class
- Riluzole
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
46 interactions on record for riluzole.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Riluzole · interactions on record
46 records
- 4 severe
- 28 moderate
- 5 minor
- 9 info
Most severe, free to view
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- LeflunomideL04AK01severe
- TeriflunomideL04AK02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Riluzole in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomEmylif 50mg orodispersible filmsZambon UK Ltd
- CzechiaRILUTEKSanofi Winthrop Industrie, Gentilly
- United StatesriluzoleGlenmark Pharmaceuticals Inc., USA
- FranceEMYLIF 50 mg, film orodispersibleZAMBON (ITALIE)
- NetherlandsEmylif 50 mg orodispergeerbare filmZambon S.p.A.
- BelgiumEmylif 50 mgZambon
- SwedenGlentek 50 mg Filmdragerad tablettGlenmark Arzneimittel GmbH
- SpainEMYLIF 50 MG PELICULA BUCODISPERSABLEZambon S.P.A.
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Emylif, Riluzol Aristo
- Belgium · Emylif, Riluzol Ab
- Cyprus · Teglutik
- Czechia · Riluzol Pmcs
- Denmark · Emylif, Glentek
- Estonia · Lizolorol, Rilustad
- Spain · Emylif, Riluzol Aurovitas
- Finland · Teglutik
- France · Emylif, Riluzole Arrow
- United Kingdom (Northern Ireland) · Emylif, Riluzole Accord Healthcare
- Greece · Teglutik
- Croatia · Alsemol
- Hungary · Sclefic
- Iceland · Emylif, Rilutek
- Italy · Emylif, Riluzolo Aurobindo
- Liechtenstein · Rilutek, Riluzole Zentiva
- Luxembourg · Emylif, Teglutik
- Netherlands · Emylif, Glentek
- Norway · Emylif, Rilutek
- Poland · Riluzol Pmcs, Riluzole Sun
- Portugal · Emylif, Riluzol Aurovitas
- Romania · Riluzol Pmcs
- Sweden · Emylif, Glentek
- Slovenia · Sclefic
- Slovakia · Riluzol Pmcs
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ecb4cab2-d237-4176-a077-55393742a27d GET /v1/drugs/ecb4cab2-d237-4176-a077-55393742a27d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Gastroenteral Use ,Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Riluzole",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about riluzole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.